Abstract: Treatment of Alzheimer’s disease (AD) is a major public health issue, with the potential for significant impact on MCOs. As the number of people affected with AD continues to rise, the importance of this problem will grow as well. This article reviews patient and caregiver outcomes associated with reduced health care costs and their implications for MCOs. Cholinesterase inhibitors (ChEIs) are effective in treating cognitive, functional, and behavioral symptoms for patients with mild to moderate and moderate to severe AD. Treatment with memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has been shown to benefit patients with moderate to severe AD. Pharmacoeconomic studies indicate that donepezil and memantine treatment may reduce total costs of care for AD patients and their caregivers, with potential economic benefits to MCOs.
Author correspondence:
David S. Geldmacher, MD
Director, Memory Disorders Program
Associate Professor
Department of Neurology
University of Virginia Health System
Charlottesville, VA
More like this
- Alzheimer’s Drug Pipeline Is Robust, and Usage Is Quickly Expanding
- AHCPR Releases Last Guidelines: Diagnosing Early Alzheimer’s
- Alzheimer’s Deaths More Than Estimated
- A Conversation with Jeff Goldsmith: He Connects Health Care’s Dots Along Information Superhighway
- Obstructive Lung Diseases — Asthma and COPD: Managing the Patient and the Costs
Our most popular topics on Managedcaremag.com
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweißen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.